Login / Signup

TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.

Mark C MarkowskiCora N SternbergHao WangTingchang WangLaura LinvilleCatherine H MarshallRana SullivanSerina KingTamara L LotanEmmanuel S Antonarakis
Published in: The oncologist (2024)
Rucaparib can induce clinical responses in a biomarker-selected metastatic prostate cancer population without concurrent ADT. However, the pre-specified efficacy threshold was not met, and enrolment was truncated. Although durable responses were observed in a subset of patients, further study of PARPi treatment without ADT in mHSPC is unlikely to change clinical practice.
Keyphrases